Sensors (Jun 2023)

Automatic Assessment of the 2-Minute Walk Distance for Remote Monitoring of People with Multiple Sclerosis

  • Spyridon Kontaxis,
  • Estela Laporta,
  • Esther Garcia,
  • Matteo Martinis,
  • Letizia Leocani,
  • Lucia Roselli,
  • Mathias Due Buron,
  • Ana Isabel Guerrero,
  • Ana Zabala,
  • Nicholas Cummins,
  • Srinivasan Vairavan,
  • Matthew Hotopf,
  • Richard J. B. Dobson,
  • Vaibhav A. Narayan,
  • Maria Libera La Porta,
  • Gloria Dalla Costa,
  • Melinda Magyari,
  • Per Soelberg Sørensen,
  • Carlos Nos,
  • Raquel Bailon,
  • Giancarlo Comi,
  • on behalf of the RADAR-CNS Consortium

DOI
https://doi.org/10.3390/s23136017
Journal volume & issue
Vol. 23, no. 13
p. 6017

Abstract

Read online

The aim of this study was to investigate the feasibility of automatically assessing the 2-Minute Walk Distance (2MWD) for monitoring people with multiple sclerosis (pwMS). For 154 pwMS, MS-related clinical outcomes as well as the 2MWDs as evaluated by clinicians and derived from accelerometer data were collected from a total of 323 periodic clinical visits. Accelerometer data from a wearable device during 100 home-based 2MWD assessments were also acquired. The error in estimating the 2MWD was validated for walk tests performed at hospital, and then the correlation (r) between clinical outcomes and home-based 2MWD assessments was evaluated. Robust performance in estimating the 2MWD from the wearable device was obtained, yielding an error of less than 10% in about two-thirds of clinical visits. Correlation analysis showed that there is a strong association between the actual and the estimated 2MWD obtained either at hospital (r = 0.71) or at home (r = 0.58). Furthermore, the estimated 2MWD exhibits moderate-to-strong correlation with various MS-related clinical outcomes, including disability and fatigue severity scores. Automatic assessment of the 2MWD in pwMS is feasible with the usage of a consumer-friendly wearable device in clinical and non-clinical settings. Wearable devices can also enhance the assessment of MS-related clinical outcomes.

Keywords